ライフサイエンスコーパス: chelation therapy

1 t side effects associated with systemic EDTA chelation therapy.

2 last decade has ushered in a new era in iron chelation therapy.

3 = 45 microg/dL, the threshold for initiating chelation therapy.

4 information to liver and cardiac iron during chelation therapy.

5 d potential therapeutic agents for metal-ion chelation therapy.

6 of MDS to fully evaluate the benefit of iron chelation therapy.

7 sted of RBC transfusions and, for some, iron chelation therapy.

8 y recent discoveries and novel approaches to chelation therapy.

9 Eight patients had siderosis and underwent chelation therapy.

10 d and should not be used to direct long-term chelation therapy.

11 to 2012 after universal availability of iron chelation therapy.

12 g 330 patients who had received deferoxamine chelation therapy, 224 (68%) reported no complications.

13 y reduced cardiac iron more effectively than chelation therapy alone.

14 lt and pediatric patients need to begin iron chelation therapy and to monitor their progress.

15 ly positive results of TACT (Trial to Assess Chelation Therapy), and a body of epidemiological data s

16 of MDS may not be the major benefit of iron chelation therapy, and present evidence suggesting a pot

17 Current protocols for chelation therapy appear ineffective in preventing such

18 nse of non-transferrin-bound iron (NTBPI) to chelation therapy are largely unknown and have important

19 organ dysfunction, and complications of iron chelation therapy are strongly age-dependent in North Am

20 ent primarily relies on transfusion and iron-chelation therapy, as well as splenectomy in specific ca

21 may exist in the aging lens, suggesting that chelation therapy could be beneficial in delaying catara

22 aken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers c

23 obile state, confirming the relevance of the chelation therapy currently used to treat Mn intoxicatio

24 The trial to assess chelation therapy demonstrated a significant (P=0.035) 1

25 with a history of myocardial infarction,EDTA chelation therapy did not have a detectable effect on QO

26 ient evidence to indicate the routine use of chelation therapy for all post-myocardial infarction pat

27 e within normal limits, suggesting that iron-chelation therapy for FRDA may be problematic.

28 To evaluate the possible role of iron-chelation therapy for FRDA, we measured serum iron and f

29 ildren < 5 years of age in need of emergency chelation therapy for lead poisoning.

30 not sufficient to support the routine use of chelation therapy for treatment of patients who have had

31 Recent developments in gene and chelation therapy give hope of better prognosis for pati

32 EDTA chelation therapy has been in off-label use for the trea

33 During chelation therapy, high levels of gadolinium in excreted

34 Mitochondrial iron chelation therapy improved colitis and demonstrated an e

35 if mimicked by designer drugs, could impact chelation therapies in iron-overload diseases.

36 After institution of iron chelation therapy in 2010, no child with thalassemia maj

37 The success of chelation therapy in controlling iron overload in patien

38 The role of iron chelation therapy in myelodysplastic syndrome (MDS) rema

39 No data support the role of chelation therapy in this population.

40 e trials to examine the potential benefit of chelation therapy in this setting.

41 es an update on advances in the area of iron chelation therapy, including new indications and uses of

42 etrospective analysis demonstrates that iron chelation therapy is associated with prolonged survival

43 ve as any lead chelator currently available, chelation therapy is not indicated for children with the

44 issues in clinical trials, herbal medicine, chelation therapy, mind/body (meditation) therapy, and a

45 overload correlated with lower compliance to chelation therapy (P<0.013).

46 measures included environmental remediation, chelation therapy, public health education, and control

47 Charges for patients who required chelation therapy ranged from $31 143 to $50 852 per pat

48 cardiac siderosis, amlodipine combined with chelation therapy reduced cardiac iron more effectively

49 eposits was associated with lower anti-tumor chelation therapy response.

50 Institutes of Health.funded Trial to Assess Chelation Therapy (TACT) randomized 1708 stablecoronary

51 The Trial to Assess Chelation Therapy (TACT) showed clinical benefit of an E

52 The trial to assess chelation therapy was a $30 million National Institutes

53 ne thalassemic patients without a history of chelation therapy were included as a control group.

54 derate strength recommendation to begin iron chelation therapy when indicated.

55 blind, placebo-controlled trial of oral iron chelation therapy with deferasirox in this population.

56 Chelation therapy with disodium EDTA has been used for m